

ARG R&D Investor Day Agenda

Advancing Towards argenx 2025

Tim Van Hauwermeiren, Chief Executive Officer and Co-Founder, argenx

Efgartigimod: Differentiation of our Anti-FcRn Fc Fragment

Hans de Haard, Chief Scientific Officer and Co-Founder, argenx

Fifth Indication: Myositis

Bas van der Woning, Research Fellow, argenx

Sixth Indication: Bullous Pemphigoid

Peter Verheesen, Research Fellow, argenx

Myositis and Bullous Pemphigoid Panel

Moderated by Albert Kovera, Global Marketing, argenx

- Rohit Aggarwal, MD, MS – University of Pittsburgh
 - Russell P. Hall III, MD – Duke University
-

ARGX-117 Phase 1 Data | New Biology Insights for Multifocal Motor Neuropathy

Olivier Van de Steen, Medical Director, argenx

Inge Van de Walle, Principal Scientist, argenx

Q&A